Study on the combined nursing for retinopathy of prematurity treated with intravitreal injection of anti -vascular endothelial growth factor drugs
XU Yueyuan1 LI Yingjie1▲ ZHU Xuan1 YOU Xiaohua2
1.Department of Ophthalmology, the First Hospital of Nanchang, Jiangxi Province, Nanchang 330000, China;
2.Department of Physical Examination, the First Hospital of Nanchang, Jiangxi Province, Nanchang 330000, China
Abstract:Objective To investigate the clinical effect of combined nursing intervention in retinopathy of prematurity(ROP) treated with intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Methods A total of 60 infants with ROP admitted to Department of Ophthalmology, the First Hospital of Nanchang from January 2019 to December 2021 were selected as the research objects. They were divided into the observation group and the control group by random number table method, with 30 cases in each group. Both groups were treated with intravitreal injection of anti-VEGF drugs.The observation group received ward combined with operating room optimized nursing,and the control group received routine nursing intervention. The two groups were compared in terms of clinical effect, and the total incidence rates of adverse events such as dyspnea, asphyxia, gas accumulation in vitreous cavity, infection, retinal detachment and endophthalmitis. Results The total treatment response rate showed no statistically significant difference between the two groups (P>0.05). The total incidence of adverse events in the observation group was lower than in the control group, with statistically significant difference (P<0.05). Conclusion Combined nursing intervention for infants with ROP treated with intravitreal injection of anti-VEGF drugs can effectively reduce postoperative adverse events and improve the prognosis.
徐月圆,李颖洁,朱璇,游小华. 玻璃体腔注射抗血管内皮生长因子药物治疗早产儿视网膜病变联合护理研究[J]. 中国当代医药, 2022, 29(24): 170-172.
XU Yueyuan,LI Yingjie,ZHU Xuan,YOU Xiaohua. Study on the combined nursing for retinopathy of prematurity treated with intravitreal injection of anti -vascular endothelial growth factor drugs. 中国当代医药, 2022, 29(24): 170-172.
Quinn GE,Barr C,Bremer D,et al.Changes in Course of Retinopathy of Prematurity from 1986 to 2013 Comparison of Three Studies in the United States[J].Ophthalmology,2016,123(7):1595-1600.
Stahl A,Lepore D,Fielder A,et al.Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW):An open-label randomised controlled trial[J].Lancet,2019,394(10208):1551-1559.
Vanderveen DK,Melia M,Yang MB,et al.Anti -Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity:A Report by the American Academy of Ophthalmology[J].Ophthalmology,2017,124(5):619-633.